Antagonists of PD-1 and PD-L1 in Cancer Treatment von Lipson, Evan J, Forde, Patrick M, Hammers, Hans-Joerg, Emens, Leisha A, Taube, Janis M, Topalian, Suzanne L

Volltext

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial von Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

Volltext

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial von Motzer, Robert J, Rini, Brian I, McDermott, David F, Redman, Bruce G, Kuzel, Timothy M, Harrison, Michael R, Vaishampayan, Ulka N, Drabkin, Harry A, George, Saby, Logan, Theodore F, Margolin, Kim A, Plimack, Elizabeth R, Lambert, Alexandre M, Waxman, Ian M, Hammers, Hans J

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial von Cella, David, Grünwald, Viktor, Escudier, Bernard, Hammers, Hans J, George, Saby, Nathan, Paul, Grimm, Marc-Oliver, Rini, Brian I, Doan, Justin, Ivanescu, Cristina, Paty, Jean, Mekan, Sabeen, Motzer, Robert J

Volltext

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas von Zeng, Jing, MD, See, Alfred P., BS, Phallen, Jillian, BS, Jackson, Christopher M., BA, Belcaid, Zineb, MS, Ruzevick, Jacob, BS, Durham, Nicholas, BS, Meyer, Christian, MD, PhD, Harris, Timothy J., MD, PhD, Albesiano, Emilia, PhD, Pradilla, Gustavo, MD, Ford, Eric, PhD, Wong, John, PhD, Hammers, Hans-Joerg, MD, PhD, Mathios, Dimitris, MD, Tyler, Betty, BS, Brem, Henry, MD, Tran, Phuoc T., MD, PhD, Pardoll, Drew, MD, PhD, Drake, Charles G., MD, PhD, Lim, Michael, MD

Volltext

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

Volltext

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma von Motzer, Robert J., McDermott, David F., Escudier, Bernard, Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Barthélémy, Philippe, Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Gurney, Howard, Kollmannsberger, Christian K., Grimm, Marc‐Oliver, Barrios, Carlos, Tomita, Yoshihiko, Castellano, Daniel, Grünwald, Viktor, Rini, Brian I., McHenry, M. Brent, Lee, Chung‐Wei, McCarthy, Jennifer, Ejzykowicz, Flavia, Tannir, Nizar M.

Volltext

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlle... von Motzer, Robert J, Rini, Brian I, McDermott, David F, Arén Frontera, Osvaldo, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, Tannir, Nizar M

Volltext

The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma von Amin, Asim, Hammers, Hans

Volltext

Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database von Singla, Nirmish, Hutchinson, Ryan C., Ghandour, Rashed A., Freifeld, Yuval, Fang, Dong, Sagalowsky, Arthur I., Lotan, Yair, Bagrodia, Aditya, Margulis, Vitaly, Hammers, Hans J., Woldu, Solomon L.

Volltext

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma von Chen, Linda, Douglass, Jacqueline, Kleinberg, Lawrence, Ye, Xiaobu, Marciscano, Ariel E., Forde, Patrick M., Brahmer, Julie, Lipson, Evan, Sharfman, William, Hammers, Hans, Naidoo, Jarushka, Bettegowda, Chetan, Lim, Michael, Redmond, Kristin J.

Volltext

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study von Hammers, Hans J, Plimack, Elizabeth R, Infante, Jeffrey R, Rini, Brian I, McDermott, David F, Lewis, Lionel D, Voss, Martin H, Sharma, Padmanee, Pal, Sumanta K, Razak, Albiruni R Abdul, Kollmannsberger, Christian, Heng, Daniel Y C, Spratlin, Jennifer, McHenry, M Brent, Amin, Asim

Volltext

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial... von Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

Volltext

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab von McDermott, David F, Drake, Charles G, Sznol, Mario, Choueiri, Toni K, Powderly, John D, Smith, David C, Brahmer, Julie R, Carvajal, Richard D, Hammers, Hans J, Puzanov, Igor, Hodi, F Stephen, Kluger, Harriet M, Topalian, Suzanne L, Pardoll, Drew M, Wigginton, Jon M, Kollia, Georgia D, Gupta, Ashok, McDonald, Dan, Sankar, Vindira, Sosman, Jeffrey A, Atkins, Michael B

Volltext

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors von Gul, Anita, Stewart, Tyler F, Mantia, Charlene M, Shah, Neil J, Gatof, Emily Stern, Long, Ying, Allman, Kimberly D, Ornstein, Moshe C, Hammers, Hans J, McDermott, David F, Atkins, Michael B, Hurwitz, Michael, Rini, Brian I

Volltext

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 von Escudier, Bernard, Motzer, Robert J, Sharma, Padmanee, Wagstaff, John, Plimack, Elizabeth R, Hammers, Hans J, Donskov, Frede, Gurney, Howard, Sosman, Jeffrey A, Zalewski, Pawel G, Harmenberg, Ulrika, McDermott, David F, Choueiri, Toni K, Richardet, Martin, Tomita, Yoshihiko, Ravaud, Alain, Doan, Justin, Zhao, Huanyu, Hardy, Helene, George, Saby

Volltext

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT von Rowe, Steven P., Gorin, Michael A., Hammers, Hans J., Som Javadi, M., Hawasli, Hazem, Szabo, Zsolt, Cho, Steve Y., Pomper, Martin G., Allaf, Mohamad E.

Volltext

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study von Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J

Volltext